3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Neoplasms
17
Breast Neoplasms
10
Carcinoma, Non-Small-Cell Lung
9
Neoplasm Metastasis
6
Prostatic Neoplasms
5
Melanoma
5
Lung Neoplasms
5
Solid Tumor
3
Pain, Postoperative
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Leukemia, Myeloid, Acute
3
Gastrointestinal Stromal Tumors
3
Colorectal Neoplasms
3
Anxiety Disorders
3
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Pain
2
Glioma
2
Colonic Neoplasms
2
Choledocholithiasis
2
Choledochal Cyst
2
Carcinoma
2
Advanced Solid Tumor
2
Advanced Malignancies
2
cMET-dysregulated Advanced Solid Tumors
1
Urothelial Cancer
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Interventions
Doxorubicin
25
Gemcitabine
16
Trabectedin
12
Ifosfamide
12
Radiotherapy
11
Docetaxel
10
Dacarbazine
8
pazopanib
7
Nivolumab
6
Specimen Handling
5
liposomal doxorubicin
4
Temozolomide
4
Biopsy
4
pembrolizumab
3
Sunitinib
3
Sorafenib
3
Radiation
3
Magnetic Resonance Spectroscopy
3
Filgrastim
3
rucaparib
2
pegfilgrastim
2
olaratumab
2
eribulin
2
durvalumab
2
cixutumumab
2
cemiplimab
2
brostallicin
2
belinostat
2
avelumab
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Leiomyosarcoma
×
Midazolam
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled